secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001159036-26-000023
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme full-year 2025 revenue $1.397B (up 38%), royalty record $868M; 2026 guidance reiterated
--------------------------------------------------------------------------------

- FY2025 total revenue $1.397B (+38% YoY); royalty revenue $868M (+52%) led by VYVGART Hytrulo, DARZALEX SC, Phesgo.
- GAAP net income $316.9M ($2.56 diluted EPS) includes $284.9M IPR&D charge for Surf Bio acquisition; adjusted EBITDA $657.6M.
- Q4 2025 revenue $451.8M (+52% YoY); net loss $141.6M due to Surf Bio charge; adjusted EBITDA $21.9M.
- 2026 guidance: total revenue $1.71–1.81B (growth 22–30%), royalty $1.13–1.17B, adjusted EBITDA $1.125–1.205B, non-GAAP EPS $7.75–8.25.
- Expanded delivery portfolio via Elektrofi and Surf Bio acquisitions; completed $1.5B convertible note offering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903626000023/0001159036-26-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903626000023/halo-20260217.htm
  HTML page:      https://secwatch.observer/filing/0001159036-26-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer